In this report, we describe a series of clonal events in an elderly patient originally diagnosed with JAK2 V617F-positive ET who presented in accelerated phase, with subsequent progression to concurrent myeloid sarcoma (MS) and B-cell ALL. Here, JAK2 is linked to essential thrombocythemia.